Swiss pharma firm Novartis acquires US biotech Mariana Oncology for $1bn upfront and $750m in milestones, targeting cancer drug pipeline expansion.

Novartis, a Swiss pharma firm, is acquiring US biotech Mariana Oncology for $1bn upfront, with $750m in milestone payments. The deal aims to strengthen Novartis' targeted cancer drugs pipeline and complements its existing portfolio of radioligand therapies. Mariana Oncology focuses on developing novel radioligand therapies for cancer treatment.